The magnitude of antigen-specific IFNγ-secreting cells, as measured by ELISpot, showed correlation towards survival after the administration of a prostate-specific antigen vaccine in prostate cancer patients, as well as a human epidermal growth factor receptor 2 (HER2/neu) specific vaccine in breast cancer patients [24–26]. This evidence concerns the gene ERBB2 and breast cancer.